ArticleNature immunology2023
Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8
Open access · hybridAbstract read
In one paragraph
Article in Nature immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
10.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 44 citations in OpenAlex.
- Systemic pre-conditioning favors effector over exhausted CD8 T-cell subsets following Sup2-IL33 armored CAR T-cell therapy.Journal for immunotherapy of cancer · 2026Article
- T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Chimeric MHC class I- and II-restricted non-self epitopes broaden antitumor T cell reactions.The Journal of experimental medicine · 2026Article
- Generation and Characterization of CAR-T Cells.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Autocrine activity of engineered IL-33 mRNA enhances adoptive T-cell therapy for peritoneal carcinomatosis and synergizes with IL-12 mRNA.Theranostics · 2026Article
- Review
- Epigenetic regulation of T cell exhaustion in cancer.Nature reviews. Cancer · 2026Review
- Peptide-MHC-targeted retroviruses enable in vivo expansion and gene delivery to tumor-specific T cells.Science advances · 2025Article
- Unlocking IL-33: New Insights into Tumor Immunity.Immune network · 2025Review
- Tumor-associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers.Cancer discovery · 2025Article
- sPGGM: a sample-perturbed Gaussian graphical model for identifying pre-disease stages and signaling molecules of disease progression.National science review · 2025Article
- Gamma-retrovirus design for efficacious microRNA-mediated gene knock-down and protein co-expression without compromising titers.NAR molecular medicine · 2025Article
- IL-2 immunotherapy rescues irradiation-induced T cell exhaustion in mouse colon cancer.iScience · 2025Article
- CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors.Journal for immunotherapy of cancer · 2025Article
- Immunogenic clearance combined with PD-1 blockade elicits antitumor effect by promoting the recruitment and expansion of the effector memory-like CD8Translational oncology · 2025Article
- Preclinical model for evaluating human TCRs against chimeric syngeneic tumors.Journal for immunotherapy of cancer · 2024Article
- Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach.Nature reviews. Clinical oncology · 2024Review
- Dual ON/OFF-switch chimeric antigen receptor controlled by two clinically approved drugs.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Focusing on CD8Journal of experimental & clinical cancer research : CR · 2024Review
- Integrating mechanism-based T cell phenotypes into a model of tumor-immune cell interactions.APL bioengineering · 2024Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 3 institutions in 1 country.
Jesus Corria-OsorioLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland. angeldejesus.corriaosorio@unil.ch.ORCID http://orcid.org/0000-0001-6844-6170
Santiago J CarmonaLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.ORCID http://orcid.org/0000-0002-2495-0671
Evangelos StefanidisLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
Massimo AndreattaLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.ORCID http://orcid.org/0000-0002-8036-2647
Yaquelin Ortiz-MirandaLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.ORCID http://orcid.org/0000-0002-9136-6205
Tania MullerLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
Ioanna A RotaLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
Isaac CrespoLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
Bili SeijoLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
Wilson CastroLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.ORCID http://orcid.org/0000-0002-9649-9883
Cristina Jimenez-LunaLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.ORCID http://orcid.org/0000-0002-2395-1728
Leonardo ScarpellinoDepartment of Immunobiology, University of Lausanne, Epalinges, Switzerland.
Catherine RonetLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
Aodrenn SpillLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
Evripidis LanitisLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
Pedro RomeroLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.ORCID http://orcid.org/0000-0002-9688-2882
Sanjiv A LutherDepartment of Immunobiology, University of Lausanne, Epalinges, Switzerland.ORCID http://orcid.org/0000-0002-8758-957X
Melita IrvingLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.ORCID http://orcid.org/0000-0002-6849-7194
George CoukosLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland. george.coukos@chuv.ch.ORCID http://orcid.org/0000-0001-8813-7367
Ludwig Cancer Research · CHUniversity of Lausanne · CHUniversity Hospital of Lausanne · CH
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, no immunotherapy approaches have managed to fully overcome T-cell exhaustion, which remains a mandatory fate for chronically activated effector cells and a major therapeutic challenge. Understanding how to reprogram CD8
Indexed as
CD8-Positive T-LymphocytesImmunotherapy, AdoptiveInterleukin-2Neoplasms, ExperimentalAnimalsCell Line, TumorFemaleInterleukin-33Lymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLProgrammed Cell Death 1 ReceptorProtein EngineeringT-Cell ExhaustionInterleukin-2Interleukin-33Programmed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.